1 Introduction
2 Methodology
2.1 Fate and exposure
2.1.1 The UCrad methodology
2.2 Dose response and severity: approach and data sources
2.3 Case study
3 Results
3.1 Effect factors
Cancer | Dose response factor | Severity factor | Effect factor | |
---|---|---|---|---|
Cancer cases* per 10,000 persons/Sv | DALY/cancer case | DALY/Sv | Contribution to aggregated effect factor** | |
Oesophagus | 15 | 12.14 | 1.82E−02 | 3% |
Stomach | 79 | 8.19 | 6.47E−02 | 11% |
Colon | 65 | 2.12 | 1.38E−02 | 2% |
Liver | 30 | 21.45 | 6.43E−02 | 11% |
Lung | 114 | 14.28 | 1.63E−01 | 27% |
Bone | 7 | 2.73 | 1.91E−03 | 0% |
Skin | 1000 | 0.53 | 5.32E−02 | 9% |
Breast | 112 | 1.07 | 1.20E−02 | 2% |
Ovarian | 11 | 4.44 | 4.89E−03 | 1% |
Bladder | 43 | 1.53 | 6.58E−03 | 1% |
Thyroid | 33 | 0.67 | 2.22E−03 | 0% |
Bone marrow | 42 | 2.04 | 8.58E−03 | 1% |
Remainders | 144 | 2.60 | 3.75E−02 | 6% |
Heritable | 20 | 78.21 | 1.56E−01 | 26% |
Total | 6.07E−01 |